Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178676 | 0.86 | HTR2A (0.43) | HTR2AHTR2CHTR2BTMEM97SIGMAR1 | |
| SCHEMBL26575964 | 0.82 | KCNH2 (0.38) | HTR2AHTR2CHTR2BTMEM97SIGMAR1 | |
| SCHEMBL20178633 | 0.79 | HTR2A (0.41) | HTR2AHTR2CHTR2BKIF11AR | |
| SCHEMBL20178632 | 0.76 | HTR2A (0.38) | HTR2AHTR2CHTR2BKIF11AR | |
| SCHEMBL12938174 | 0.73 | TMEM97 (0.35) | TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13938028 | 0.71 | TMEM97 (0.54) | HTR2BTMEM97SIGMAR1KCNH2 | |
| SCHEMBL16854830 | 0.71 | HTR2C (0.39) | HTR2AHTR2CHTR2BAR | |
| SCHEMBL20173788 | 0.71 | PDE2A (0.35) | HTR2AHTR2CHTR2BTMEM97SIGMAR1 | |
| SCHEMBL26575966 | 0.70 | HRH3 (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL20119408 | 0.70 | ACACB (0.40) | HTR2BTMEM97SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141941-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | NR1H4, FXR1, SLC10A1 | HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | HTR2A 3895/4885HTR2C 2204/4885HTR2B 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.